Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019829 (
Hodgkin's disease
)
30,247
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Antiserum was generated in rabbits to the RPMI 8226 tissue culture line of human myeloma cells, and its reactions with fixed smears of bone marrow aspirates from patients with multiple myeloma, macroglobulinemia, benign monoclonal gammopathy (BMG), leukemia, and nonneoplastic plasmacyosis was assessed by indirect immunofluorescence. After absorption with preparations of bone marrow from normal individuals, the antiserum reacted to a significantly higher titer with a specific subpopulation of plasma cells in smears from 81% of patients having multiple myeloma and 50% of patients having BMG than with cells in smears of bone marrow aspirates from normal individuals or patients having leukemia or nonneoplastic plasmacytosis, or than with cells in smears of peripheral blood from patients having
Hodgkin
's and
non-Hodgkin's lymphoma
. Absorption of the antiserum with RPMI 8226 cells or with a bone marrow preparation from a patient with multiple myeloma but not the Jijoye line of Burkitt's lymphoma reduced reactivity for cells in myeloma bone marrow. The antiserum reacted at a lower titer with the Jijoye and EB-3 lines of Burkitt's lymphoma, the RPMI 4098 cell line of normal human lymphocytes, and culture lines of human melanoma and osteogenic sarcoma than with the RPMI 8226 cells or bone marrow from certain patients having multiple myeloma. Approximately 50% of the cells reactive with antiserum to RPMI 8226 cells in the bone marrow of patients with multiple myeloma were not producing immunoglobulin, as assessed by double immunofluorescence assay. The data suggested that a subpopulation of plasma cells in the bone marrow of patients with multiple myeloma possesses a tumor-associated antigen.
...
PMID:Tumor-associated antigens in human myeloma. 5 51
A modified electrophoretic mobility (EM) test was performed in 150 children to examine their lymphocyte sensitization to myelin basic protein (encephalitogenic factor). Measurements in the cytopherometer were facilitated by using devitalized sheep erythrocytes as indicator particles instead of macrophages. A significant decrease in EM was found in 29/30 children with acute lymphoblastic leukaemia and in 67/75 children with solid tumours, thus giving a false negative rate in malignant disease of 9/105=8-6%, as compared to 6 false positives among 45 children with non-malignant disorders; 5 of the later "false/positive" 6 patients had autoimmune disease. Results of the EM test in the children with leukaemia were compared with those in 9 patients with
non-Hodgkin's lymphoma
and 2 with
Hodgkin's disease
at different stages, but no striking change was seen between different diseases, or after cessation of long-term immunosuppressive chemotherapy. Percentage of "slowing" ranged from 4 to 30%. These results indicate that patients with lymphoid malignancies still have lymphocytes which had been sensitized by a common antigen of the malignant cell clone at the beginning of the disease. The EM test, furthermore, could serve as an additional diagnostic aid in differentiating benign from malignant masses in the abdomen, extremities or intracranial disease.
...
PMID:Lymphocyte sensitization in childhood solid tumours and lymphoblastic leukaemia, measured by electrophoretic mobility test. 6 84
Total-body scintigraphy with 111In-labeled bleomycin was performed in 66 patients with malignant solid tumors and systemic diseases of the lymphatic pathways (
Hodgkin's lymphoma
and
non-Hodgkin's lymphoma
). In 38 (58%) of 66 cases positive information was correct. In 12 (18%) of 66, scintigraphic information was correctly negative. With 16 out of 66 (24%), false positive or false negative informations were obtained.
...
PMID:[Localization diagnostics of malignant tumors using radioactive bleomycin (author's transl)]. 6 44
The effectiveness of computed body tomography (CT) in the workup, treatment planning, and follow-up of 38 patients with
Hodgkin's disease
and 59 with
non-Hodgkin's lymphoma
was analyzed. CT scanning can frequently define lymphoma in the retroperitoneum, and occasionally in mesenteric lymph nodes, spleen, and liver. These data are useful for staging, for radiotherapy treatment planning, and in monitoring response to radiotherapy or chemotherapy. CT was found to be particularly useful in patients with large mediastinal masses. Analysis of patterns of intrathoracic spread allowed modification of treatment techniques in 60% of patients with spread along the chest wall, in order to reduce the volume of normal tissue irradiated, while obtaining adequate dose distributions within the tumor volume. It is anticipated that chest CT scanning in lymphoma patients will lead to improved tumor control and reduction of radiation complications.
...
PMID:Contribution of computed tomography to the treatment of lymphomas. 9 88
The physiocochemical and immunological properties of alkaline phosphatase extracted from
Hodgkin
's nodes,
non-Hodgkin's lymphoma
nodes and leukemic leukocytes have been studied. The alkaline phosphatase from these three tumor types possesses the same biophysical and biochemical properties and immunological determinants as the placental alkaline phosphatase. However, it is more heat-labile than the placental isoenzyme. Immunological experiments indicate that, of these tumor types,
Hodgkin
's tumor contains the largest amounts of heat-labile Regan type of alkaline phosphatase.
...
PMID:Occurrence of heat-labile Regan type of alkaline phosphatase in hematopoietic tumors. 11 39
From 1961 to 1969 426 patients (208 with
Hodgkin's disease
and 218 with
non-Hodgkin's lymphoma
) underwent endolympatic radiotherapy with Lipiodol 131I at the National Cancer Institute of Milano. For this study, only those patients with stage I, II, or III disease (with or without systemic symptoms), who were not previously treated, and who had a complete follow-up were reviewed. It appears that while in the cases where there is lymphographic evidence of involved lymph nodes, endolymphatic radiotherapy is not of value, in the cases with apparently negative lymphography, endolymphatic radiotherapy can reduce the incidence of relapse in the inguino-retroperitoneal nodes to a statistically significant degree.
...
PMID:Endolymphatic radiotherapy in malignant lymphomas: its potential "prophylactic" value in cases with negative lymphograms. 17 43
One hundred and ten skin infections with herpes virus were seen in a uniform group of 1,002 lymphoma-leukaemias dominated by
non-Hodgkin's lymphoma
(385) and
Hodgkin's Disease
(327). They appeared with a significantly increased frequency in the course of
Hodgkin's Disease
, and between the ages of 60 and 69 for the other groups. In the
Hodgkin
's cases they appeared characteristically during complete remission and in the others during the active phase of their disease. Only exceptionally was there evidence of contact infection. Also these infections seemed mainly due to the re-awakening of a latent virus infection as against a failure of natural defense mechanisms of the organism, which the disease itself and the therapeutic regime might alter in a variable fashion.
...
PMID:[Cutaneous herpesvirus infections and malignant blood disorders. Epidemiology]. 18 72
The leukocyte adherence inhibition (LAI) assay was utilized as a test for cellular immunity to Epstein-Barr virus (EBV) antigens in 22 patients with infectious mononucleosis (IM), 47 patients with lymphoma, 101 carcinoma patients, and 84 subjects without cancer. Response to EB virion ("v") antigen was generally present at the time of diagnosis in the IM patients but the response to EB soluble ("S") antigen was delayed. An increased CMI response to "v" antigen was found in patients with IM,
Hodgkin's disease
and
non-Hodgkin's lymphoma
as compared to controls with and without cancer. Patients with
Hodgkin's disease
had depressed responses to the EBV-associated "S" antigen. The finding of increased LAI responses to "v" antigen in
Hodgkin's disease
patients with high EBV antibody titers conflicts with previous reports attributing high antibody responses against EBV to a generalized depressed cell-mediated immunity.
...
PMID:Lymphocyte responses to EBV-associated antigens in infectious mononucleosis, and Hodgkin's and non-Hodgkin's lymphoma patients, with the leukocyte adherence inhibition assay. 19 8
During the period of three years ((1972-1974), serum samples from 60 patients (children and adolescents) with lympho-hematopoietic system diseases were examined for antibodies to all four human herpesviruses. Among these were 26 active
Hodgkin's disease
(AHD) patients and 6 HD patients with a minimum five years' remission. Simultaneously matched controls (age, sex) of AHD patients were examined. Antibody levels against the viral capsid antigen of Epstein-Barr virus (EBV/VCA) in AHD patients were significantly higher, with overrepresentation of higher titres (greater than or equal to 1:160), than in matched controls. The lowest EBV/VCA antibody titres were in the leukemia-
non-Hodgkin's lymphoma
patients. We could not prove any significant relationship between cytomegalovirus or herpes simplex virus type 1 antibody titres and AHD or any other disease of lympho-hematopoietic system. The varicella-zoster virus antibody titres in AHD patients were significantly higher than in matched controls. No significant differences in antibodies against EBV/VCA and the other human herpes viruses between the evolution and remission period of AHD patients could be detected. No differences in EBV/VCA antibody titres were observed between the healthy school-children aged 10 to 15 years who were and who were not in contact with a HD patient.
...
PMID:Herpesvirus group antibodies in children with Hodgkin's disease. 19 63
In the past decades many changes have taken place in the classification of lymphoreticular malignancies. At present two main groups are recognized--
Hodgkin
's lymphomas and non-
Hodgkin
's lymphomas.
Hodgkin
's lymphomas rarely affect the oral cavity. The mouth, especially the soft tissues, is somewhat more frequently involved in cases of
non-Hodgkin's lymphoma
. There seems to be some predilection for the mucosa of the palate. The present report describes eight patients in whom a swelling of the palatal mucosa led to the diagnosis of
non-Hodgkin's lymphoma
. The emphasis is on the clinical and microscopic aspects. The present most accepted histologic classifications have been applied and are briefly discussed.
...
PMID:Non-Hodgkin's lymphoma of the hard palate. 22 May 79
1
2
3
4
5
6
7
8
9
10
Next >>